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Abstract
Several new human monoclonal antibodies (mAbs) with a neutralizing potential across different subtypes have recently
been described. Three mAbs, HJ16, HGN194 and HK20, were obtained from patients within the HIV-1 cohort of the Institute
of Tropical Medicine (ITM). Our aim was to generate immunization antibodies equivalent to those seen in plasma. Here, we
describe the selection and characterization of patient plasma and their mAbs, using a range of neutralization assays,
including several peripheral blood mononuclear cell (PBMC) based assays and replicating primary viruses as well as cell line
based assays and pseudoviruses (PV). The principal criterion for selection of patient plasma was the activity in an ‘extended
incubation phase’ PBMC assay. Neutralizing Abs, derived from their memory B cells, were then selected by ELISA with
envelope proteins as solid phase. MAbs were subsequently tested in a high-throughput HOS-PV assay to assess functional
neutralization. The present study indicates that the strong profiles in the patients’ plasma were not solely due to antibodies
represented by the newly isolated mAbs. Although results from the various assays were divergent, they by and large
indicate that neutralizing Abs to other epitopes of the HIV-1 envelope are present in the plasma and synergy between Abs
may be important. Thus, the spectrum of the obtained mAbs does not cover the range of cross-reactivity seen in plasma in
these carefully selected patients irrespective of which neutralization assay is used. Nevertheless, these mAbs are relevant for
immunogen discovery because they bind to the recombinant glycoproteins to which the immune response needs to be
targeted in vivo. Our observations illustrate the remaining challenges required for successful immunogen design and
development.
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Introduction
Despite intense research efforts over nearly three decades, only
minimal progress has been made in developing an HIV-1 vaccine.
In retrospect, a number of reasons can be proposed for this failure
such as the enormous genetic diversity of HIV, the camouflage of
the neutralizing epitopes in the envelope spike by glycan shields,
the presence of ‘‘decoy’’ immunodominant non-neutralizing
antigenic determinants in non-conserved areas on the surface
and the low gp120 trimer spike density on the virus membrane [1].
In addition, the most vulnerable regions may only be accessible for
a short period. These short-lived structures include the so-called
CD4 induced (CD4i) in gp120 and the pre-hairpin epitopes in
gp41 that are only exposed following CD4 receptor binding and
the subsequent conformational changes. Still, a few antibodies
(Abs) are able to successfully interfere with the binding and fusion
process, as seen in passive immunization studies in the macaque
model. Such mAbs include 2G12 (binds to mannose residues on
gp120); b12 and F105 (bind to the CD4 binding site, CD4bs); 17b
and 65 (recognize conformational epitopes in the CD4i region);
and 4E10 and 2F5 (bind to epitopes in the membrane proximal
extracellular region or MPER of gp41). Last year, however, three
new mAbs (HJ16, HGN194 and HK20) were reported from
African patients from the ITM HIV-1 cohort. Taken together
these mAbs target three different steps in viral entry: binding to
CD4bs and thus preventing interaction of HIV-1 with CD4 by
HJ16, binding to V3 and blocking the coreceptor binding by
HGN194 and finally immobilizing the unfolding of the gp41 by
the HK20 mAb [2]. Since HK20 targets HR1 instead of MPER or
glycans in this region, it has the conceptual advantage over 4E10
and 2F5 of avoiding potential auto reactivity [2,3]. Importantly,
the HGN194 mAb has recently been found to confer protection in
infant rhesus monkeys by the group of Ruprecht [4].
In order to generate these mAbs, patient plasma were selected
with a neutralization assay with an extended incubation time,
using activated PBMC and a panel of clinically isolated replication
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‘short’ PBMC neutralization assay by extending the incubation
phase of plasma with virus from 1 to 24 hours. The importance of
this format was shown in a SHIV challenge trial in rhesus
macaques, where recombinant HIV envelope immunizations
induced protection [5,6]. Comparing various neutralization assays,
we showed that the PBMC based assay with an extended
incubation phase was able to discriminate between protected
and non-protected animals after vaccination. Since we are
attempting to develop a vaccine effective against a range of
subtypes and because the subtype A, subtype C and circulating
recombinant form (CRF) 02_AG are responsible for at least 75%
of the current new infections worldwide, we identified patients,
whose plasma could cross-neutralize mainly viruses from these
three subtypes in the extended incubation PBMC assay. From the
blood of selected patients, memory B cells were isolated and
immortalized using an Epstein Barr Virus (EBV) based procedure
[7]. Supernatants of B cell clones were tested in ELISA with
recombinant gp41, trimeric gp120 and gp140 proteins from
several subtypes as solid phase. Clones with binding activity to any
of these antigens were expanded and supernatants were tested
using a HOS based PV neutralization assay. This effort ultimately
resulted in the selection of the new mAbs HJ16, HGN194 and
HK20, which showed considerable breadth of neutralizing activity
against a panel of HIV-1 primary isolates spanning both tier 1 and
tier 2 viruses of different subtypes [2].
Here, we present the characteristics of the patient’s plasma and
their respective mAbs in multiple neutralization assay formats.
The results clearly demonstrate that patient selection was highly
dependent on the neutralization assay. Although the cross-
neutralizing properties of the isolated Abs showed considerable
variation with the neutralization assay format, all assays indicate
that neutralizing Abs to other epitopes of the HIV-1 envelope are
present in the plasma and also do not exclude the role that synergy
between such Abs could play.
Materials and Methods
Ethics statement
The study was approved by the Institutional Review Board of
the Institute of Tropical Medicine and the Ethical Committee of
the University Hospital of Antwerp. All participants understood
and signed an informed consent.
Patient selection
Eligible patients visiting the ITM clinic in Antwerp had been
infected for at least one year, were clinically asymptomatic and
over 18 years old. Neither CD4 T cell counts nor viral loads were
taken into consideration. Patients were preferentially selected from
sub-Saharan regions where the subtypes A, C and/or CRF02_AG
are prevalent. Plasma was subsequently screened for its ability to
neutralize a panel of four subtype A, four subtype C and six
CRF02_AG primary HIV-1 strains, in our extended incubation
phase PBMC assay (see below).
Monoclonal antibodies
HJ16, HK20 and HGN194 Abs were obtained as part of the
Collaboration for AIDS Vaccine Discovery program from Dr. D.
Corti (Institute for Research in Biomedicine, Bellinzona, Switzer-
land).
Cells
Buffy coats from healthy donors from the Red Cross Blood
Transfusion Center at the University Hospital of Antwerp were
used for isolation of PBMC by LymfoPrep (Axis-Shield, Oslo,
Norway) centrifugation and adjusted to 1610
6/ml in culture
medium, consisting of RPMI 1640, 15% fetal calf serum (FCS),
0.03% L-glutamine and 50 mg/ml gentamycin (Lonza, Verviers,
Belgium), 2 mg/ml polybrene (Sigma-Aldrich, Bornem, Belgium).
Cells were stimulated with 0.5 mg/ml phytohemagglutinin (PHA,
Oxoid, Hampshire, UK) for 2 days and 1 day with 200 U/ml
interleukin-2 (IL-2; Gentaur, Brussels, Belgium) in a 7% CO2
incubator at 37uC and then used for neutralization assays. The
following cell lines were obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: TZMbl from Dr. John C. Kappes, Dr. Xiaoyun Wu
and Tranzyme Inc. and Ghost(3)X4/R5 from Drs. Vineet N.
KewalRamani and Dan R. Littman. HEK 293T cells were
obtained from the American Type Culture Collection, ATCC,
Virginia, US.
Replication competent HIV-1 virus and single-cycle HIV-1
pseudoviruses
For patient selection a panel of 14 primary group M isolates
representing subtypes A, C and CRF02_AG were used: four
subtype A strains (VI 191, 92UG37, VI 820, VI 1031), four
subtype C strains (VI 829, VI 882, VI 1144, VI 1358) and six
CRF02_AG strains (VI 1090, VI 2680, CI 20, CA 18, VI 1380, VI
2727). All isolates were classified by phylogenetic analysis of their
envelope genes. All virus stocks were prepared and titrated on
PHA/IL-2 stimulated PBMC. These strains have been extensively
used for at least 10 years at ITM and are considered equivalent to
neutralization resistant tier 2 viruses [8,9]. Corresponding
envelope PV constructs were obtained by DNA amplification of
the complete env starting from PBMC co-cultures or by RT-PCR
using plasma and subsequent cloning into an expression vector
(pSV7d or pcDNA4/TO) [10]. These included the ITM strains VI
191 (A), VI 829 (C), VI 882 (C), VI 1358 (C), VI 824 (D), VI 1888
(CRF01), VI 1090 (CRF02), CI 20 (CRF02) and CA 18 (CRF02).
The env expressing plasmids 92RW009 (A), SF162 (B) and
92BR025 (C) were provided by the EU Programme EVA Centre
for AIDS Reagents, NIBSC, UK (AVIP Contract Number LSHP-
CT-2004-503487). Sequencing of the PV constructs and phyloge-
netic analyses of the complete gp160 confirmed the identity of the
PV and its corresponding virus. The full length env sequences of
the ITM PV constructs have been deposited with GenBank
(accession numbers EU191613 for VI 829, EU191617 for VI
1888, EU191618 for VI 191, HQ912706 for CA 18, HQ912707
for CI 20, HQ912708 for VI 882, HQ912709 for VI 824,
HQ912710 for VI 1090 and HQ912711 for VI 1358).
Neutralization assays
Since several parameters influence the observed neutralizing
profile of a plasma or mAb, we included a comprehensive range of
different neutralization assays with distinctive characteristics.
Apart from the difference in target cell (primary cells vs. cell
lines), incubation, absorption and culture phases were also
investigated as determinants of neutralization outcome. Formats
for the different assays are as shown in Table 1.
PBMC based assays. All PBMC neutralization assays are
described as a/b/c where ‘a’ is the incubation time in hours
following mixing of mAb with virus, ‘b’ is the absorption time in
hours during which the cells are exposed to the mAb/virus
mixture. Cells are then washed and ‘c’ is the culture time in days
(all at 37uC and 7% CO2). In this study results were obtained in
24/1/14, 1/2/7 and 1/24/14 formats. These are named
‘extended incubation’, ‘short incubation’ and ‘extended
absorption’ assays respectively. The extended incubation assay,
Neutralization of Plasma vs. Antibodies
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previously [6,11]. Briefly, virus stock is diluted in a five fold series
from 1/2 to 1/6250 in culture medium (RPMI-1640 medium
supplemented with 15% FCS and 200 U/ml IL-2) to establish the
titer (-log10 if the dilution at which 50% infection is achieved). A
titer below 1 constitutes poor growth of the virus and the
experiment is discarded. Ninety ml of each virus dilution are mixed
with 5 ml of plasma or 50 mg mAb. In assays testing neutralization
by plasma the mixture is complemented with 5 ml culture medium
to give a final 1 in 20 dilution of plasma. When testing mAb, the
mixture is complemented with 5 ml flow through (IgG was
removed from HIV-1 negative plasma using a Protein G column
[GE Healthcare Europe GmbH, Belgium]) to give 50 mg/ml of
mAb. After the incubation phase 20 ml of each plasma or mAb/
virus mix are first dispensed in quadruplicate into flat bottom 96-
well microplates and 75,000 PBMC in 100 ml culture medium are
added to each well. Plates are then left in a CO2 incubator at 37uC
during the absorption phase (b). Afterwards, cells are washed three
times by centrifugation at 2000 rpm for 10 minutes, the
supernatant is aspirated and 180 ml fresh culture medium are
added to the cells. When cultured for 14 days, 125 ml of the
medium is aspirated and replaced with 135 ml fresh culture
medium. After c days, 200 ml of the supernatant are mixed with
50 ml Nonidet P40 (0.25% in PBS; Fluka, Sigma-Aldrich, Puurs,
Belgium) to disrupt virions and this mixture is analyzed for the
presence of HIV p24 antigen. As a control, pooled plasma of 100
HIV-1 negative donors are tested in parallel. For the short
incubation and extended absorption phase assays, times of
incubation are appropriately adjusted: 1/2/7 and 1/24/14
respectively. Neutralization activities are presented as the
percentage reduction in infectious titer of a virus isolate
following incubation with patient plasma or mAb relative to its
titer following incubation with HIV-1 negative control plasma.
Virus titers were calculated by the method of Reed and Muench
[12]. An 80% reduction in titer was considered significant. By
extending the usual one hour absorption phase of the extended
and short incubation PBMC assay to 24 hours (1/24/14 format)
we aimed to reproduce the conditions of the cell line based assays
where the mAbs remain during the entire absorption and culture
phase.
Pseudovirus based assays. Neutralization capacity of patient
plasma and mAbs against PV on TZMbl and the HOS cell related
GHOST.CD4-X4/R5 cells was determined as described [13,14].
Luciferase reporter gene activity was quantified 48–72 h after infection
upon cell lysis and addition of firefly luciferase substrate (Perkin-Elmer)
as described. Emitted relative light units (RLUs) were quantified on a
LB941 Berthold luminometer (Alabama, US). Infection of TZMbl cells
was quantified using SteadyLite and infection of GHOST cells was
quantified using BriteLite as a substrate (both Perkin-Elmer). In a
preliminary experiment 1.10
4 TZMbl or GHOST cells were seeded in
each well of 96-well,flat bottom plates and infected with a range of viral
doses in a total volume of 200 ml to establish the dose, which resulted in
a signal of 50,000 to 100,000 RLU in the presence of 10 mg/ml
diethylaminoethyl-dextran (DEAE-dextran, Sigma, Belgium) to
enhance virus infectivity in TZMbl cells, while no DEAE-Dextran
was used in GHOST cells. In the actual neutralization experiments,
mAbs or plasma were pre-incubated with PV for 1 h at 37uC.
The mAb concentration or plasma dilution producing a 50%
reduction in luciferase reporter gene production was determined
by linear regression analysis in Microsoft Office Excel as des-
cribed on http://www.hiv.lanl.gov/content/nab-reference-strains/
html/Protocol-for-Neutralizing-Antibody-Screening-Assay-for-HIV-1-
in-TZM-bl-Cells-November-2010.pdf. For IC50 of mAbs, the 50%
inhibitory concentrations were determined via a linear interpolation
method using the mean of duplicate or triplicate cultures. The assay
readouts for the dilutions above and below the IC50 were joined with a
straight line,plotted against the log concentration of mAb.The position
where the line crossed the 50% assay readout was taken as the IC50
estimate. Where the IC value was outside the range of concentrations
tested, it was recorded as either greater than the highest concentration
used, or less than the lowest concentration, as appropriate. An ID50 for
plasma and IC50 for Abs were calculated from a dilution series starting
from 1:20 for plasma and starting from 50 or 150 mgf o rA b s
depending on the Ab used.
Statistical methods
The virus titer was calculated within each individual experiment
using the method of Reed and Muench [12]. In the virus dilution
series, doses ranged between those infecting all cultures (100%) to
those infecting none (0%). Wells giving an OD.0.3, against a
background of 0.03–0.05 in the ELISA, were considered to be
infected. The infectious virus titer was calculated following virus
incubation with mAb/plasma. The reduction in titer was
calculated as a percentage of the virus titer following exposure
to either IgG or plasma which was pooled from 100 HIV-1
negative donors. Purified IgG from this pool was used as the
control for mAbs. Correlations were calculated using the
Spearman Rank correlation test using Prism version 5.0.
Differences or correlations between sets of data were considered
significant if p#0.05 and r.0.5.
Results
Patient neutralization profiles and clinical background
Over 1400 HIV-1 infected individuals regularly attend the clinic
at ITM. Of these, 200 patients were identified whose origin was
Table 1. Overview neutralization assays.
Assay Nomenclature Virus Incubation period Absorption period Culture period
24/1/14 PBMC extended incubation Infectious strains 24 h 1 h, then wash 14 days
1/2/7 PBMC short incubation Infectious strains 1 h 2 h, then wash 7 days
1/24/14 PBMC extended absorption Infectious strains 1 h 24 h, then wash 14 days
TZMbl_IV primary virus TZMbl Infectious strains 1 h whole culture period 2 days
TZMbl_PV TZMbl-PV Pseudo virus 1 h whole culture period 2 days
GHOST_PV GHOST-PV Pseudo virus 1 h whole culture period 3 days
HOS_PV HOS-PV Pseudo virus 1 h whole culture period 3 days
doi:10.1371/journal.pone.0025488.t001
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and/or CRF02_AG isolates are prevalent. Their plasma was
evaluated when they were therapy naı ¨ve or at least 6 months
therapy-free for the ability to neutralize primary HIV-1 strains
from the A, C and/or CRF02_AG subtypes in the 24/1/14
extended incubation phase PBMC neutralization assay. About
25% of these patients had cross-neutralizing plasma i.e. plasma
which neutralized at least 50% of strains belonging to one subtype
plus at least 25% of strains from a second. We next classified the
best responding plasma according to the HIV subtype they
preferentially neutralized: e.g. when at least three out of four of the
A or C strains (or five out of six CRF02 strains) gave greater than
80% neutralization. In Table 2 this neutralization profile is shown
for 20 patients whose memory B cells were interrogated.
According to these criteria, four patients’ plasma preferentially
neutralized subtype A strains (HGL-, HGD-, HQ- and HGN
plasma) and two were more specific for subtype C (HVDA and
HK plasma). We did not find any patients preferentially
recognizing the CRF02 strains. Three of the tested patients
neutralized subtypes A and C more than CRF02 (HMB-, HJ- and
HGR plasma), one was more C and CRF02 subtype specific
(HMQ plasma) and finally five patients displayed broad cross-
neutralizing activity over all three subtypes (HU-, HP/HM/
HGM-, HE-, HY- and HMV plasma). The remaining five
interrogated patients did not display this subtype specific behavior
(HL-, HZ-, HGP-, HR- and HMA plasma). There is no obvious
association between the subtype infecting a patient and that
neutralized by his or her plasma. The patients, from whom the
newly isolated mAb were obtained, are underlined in the first
column. Remarkably, plasma from these patients showed a rather
subtype specific neutralization profile since plasma from patient
242315 (HJ patient) neutralized mainly A and C strains, plasma
from patient 314994 (HGN patient) mainly A strains and plasma
from patient 529552 (HK patient) mainly C strains. In Table 3 the
clinical histories of these patients are summarized.
Patient 242315 from whom the CD4bs specific HJ16 mAb was
obtained was a 45 year old Congolese woman who had been
visiting our clinic since 1996. She received treatment intermittently
and consequently had a varying CD4 count and viral load. Her
neutralization profile had been obtained using plasma samples
taken after stopping anti- retroviral therapy for 6 to 11 months but
she was back on therapy at time of memory B cell interrogation for
7 months. Patients 314994-HGN and 529552-HK were not
receiving antiretroviral treatment during this study. Patient
314994 from whom the V3 crown specific mAb HGN194 was
obtained was a 41 year old woman from the Republic of Guinea
who has been regularly attending our clinic since 1998. She has
always maintained low viral loads and high CD4 T counts so far
without treatment. Her viral loads varied between undetectable
and 2,700 RNA copies/ml while her CD4 counts have fluctuated
between 550 and 960 cells/ml. Patient 529552 whose HK20 mAb
is specific for the HR1 region of gp41 was a 31 year old Ghanaian
woman. Soon after arrival in Belgium in 2005 she tested positive
for HIV. Her viral loads (1.500-40.000 RNA copies/ml) have
Table 2. Neutralizing profile of selected patient plasma against subtype A, subtype C and CRF02_AG isolates in the 24/1/14
extended incubation PBMC assay.
Subtype A Subtype C Subtype CRF02
Patient code Subtype
VI
191 92UG37
VI
820
VI
1031
VI
829
VI
882
VI
1144
VI
1358
VI
1090
VI
2680
CI
20
CA
18
VI
1380
VI
2727
HGL-plasma A 87,4 E 97,2 95,9 E 84,9 62,0 73,7 91,1 78,1 89,5 94,9 67,6 97,0
HGD-plasma B 84,9 80,9 94,8 97,7 55,3 96,9 99,7 24,1 91,1 86,2 66,1 94,2 10,9 99,9
HQ-plasma CRF02 98,5 97,7 96,6 90,0 66,1 99,3 8,8 0,0 10,9 E 99,8 97,8 98,2 99,4
HGN-plasma CRF02 80,5 96,1 87,4 55,3 91,1 63,7 74,3 93,7 91,1 73,7 88,3 97,2 96,1 E
HVDA-plasma C 24,1 70,5 86,8 66,1 0,0 99,9 91,1 86,2 89,3 66,1 41,1 90,5 69,1 0,0
HK-plasma CRF02 97,7 62,0 65,3 99,8 99,0 32,4 95,4 96,0 98,8 88,3 97,7 59,3 96,4 69,8
HMB-plasma A/C 98,8 99,9 52,1 98,2 99,9 99,9 E 80,0 54,3 80,0 91,1 94,8 55,3 78,1
HJ-plasma C 96,0 98,2 60,2 97,2 85.9 99.4 99,0 94.8 94,8 0,0 93,1 97,0 0,0 84,5
HGR-plasma B 98,7 97,8 96,0 98,7 96,0 91,1 96,9 66,1 88,8 80,0 71,2 94,8 97,0 78,1
HMQ-plasma A/CRF11 73,7 E 69,1 94,0 E 92,2 83,4 96,9 99,6 93,8 96,8 97,8 75,5 98,6
HU-plasma B/CRF03/CRF13 95,1 90,0 95,9 98,9 80,9 99,2 98,8 E 96,4 59,3 94,8 92,8 81,4 96,9
HP/HM/HGM-
plasma
CRF02 88,3 98,5 47,5 97,9 80,0 98,2 99,0 65,3 99,8 88,8 90,2 99,4 99,6 91,1
HGE-plasma A/CRF02 99,4 97,7 98,4 99,8 96,0 98,1 66,1 97,9 99,7 93,2 99,1 99,0 80,0 99,0
HY-plasma A/CRF02 66,1 99,5 99,2 99,6 80,0 98,6 99,5 98,9 94,4 99,0 84,5 88,3 98,2 93,1
HMV-plasma C 99,4 98,2 99,5 94,1 91,1 96,9 98,8 99,5 99,8 91,1 99,6 99,3 98,9 98,2
HL-plasma CRF02 80,0 66,9 53,2 80,0 84,5 98,2 22,4 53,2 80,0 63,7 79,1 99,2 94,2 73,7
HZ-plasma A/CRF02 42,5 94,8 69,1 93,5 94,4 55,3 E E 62,0 E E 80,0 85,9 E
HGP-plasma A/CRF02/CRF13/CRF09 41,1 87,4 94,2 42,5 55,3 76,6 73,7 90,9 99,2 91,9 55,3 30,8 91,9 91,7
HR-plasma CRF02 73,7 80,0 71,8 79,6 E 98,6 55,3 E 99,5 E 98,2 80,0 E 96,9
HMA-plasma A 0,0 E E 99,4 0,0 88,3 66,1 88,3 96,9 86,2 74,3 0,0 E 99,6
% Neutralization obtained with 1:20 plasma dilution, $80% reduction in virus titer is highlighted in italics, E: enhancement of infection, subtype specific neutralization in
bold: $80% neutralization with at least 75% of isolates within a subtype.
doi:10.1371/journal.pone.0025488.t002
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cells/ml) have remained relatively stable. She received HAART
therapy for a short time during pregnancy in 2008 (i.e. after
sample collection for the present study). Afterwards she resumed
relative control of her infection. It is clear that these patients
represent different disease profiles.
The neutralization profile of patient plasma was originally
determined using a panel of 14 replication competent clinical
HIV-1 isolates (four subtype A, four subtype C and six
CRF02_AG strains, Table 2). In view of the known neutralization
resistance of these isolates [6,8] they were considered to represent
‘Tier 2 like’’ strains. In the experiments represented in Table 4, an
additional panel of four subtype B, four subtype D and four
CRF01_AE strains provided us with an overview of the
neutralizing potential of the three selected patient plasma across
six subtypes with a total panel of 26 ‘‘tier 2 like’’ strains.
As can be observed, the 242315-HJ patient plasma has a very
broad neutralization spectrum with 21 of the 26 viruses neutralized,
including all the C and CRF01 strains, 75% of the subtype A, B and
D strainsand 67%of CRF02 strains. The 314994-HGN plasmahas
a narrower range, neutralizing 13/26 viruses, including all of the B
strains, 75% of the A strains, 67% of the CRF02 strains, 50% of C
strains, but none of the D nor CRF01 strains. The 529552-HK
plasma neutralized 12/26 viruses, including 75% of the C strains,
67% of the CRF02 strains, 50% of the A strains and 25% of the B,
D and CRF01 strains.
Influence of neutralization assays on plasma
neutralization profile of the three patients from whom
the new antibodies were isolated
In order to illustrate the influence of different assays on the
neutralization spectra of these selected plasma, we compared
results from all the assays shown in table 1 (except for the HOS-
PV assay). The virus panel used in this comparison consisted of
nine strains from our primary selection panel from which PV were
also available. Three strains from the standardized ‘‘NeutNet’’
panel were added: A (92RW009, tier 2), B (SF162, tier 1A) and C
(92Br025, tier 2) [15] and personal communication). Results are
shown in Table 5.
Comparingtheneutralization breadthofthe three patient plasma
in three variants of the PBMC assay, indicates that the HJ and HK
plasma neutralize much fewer viruses and the HGN plasma even
loses all significant neutralization capacity in the classical short assay
(1/2/7), implying that none of them would have been selected using
results from this assay. Prolonging the absorption phase to 24 hours
(1/24/14), to more closely resemble the cell line based assays (see
table 1), only ‘‘rescues’’ some neutralization with the HGN plasma.
No correlation was found between the results obtained in the
different PBMC assays using the Spearman Rank correlation test.
There wasa correlation between results from the 24/1/14 extended
incubation PBMC assay and those with the TZMbl assay using
replication competent ‘‘primary’’ viruses for the 242315-HJ plasma
(r=0.62, p=0.03) but not for the other 2 plasma samples. A
stronger correlation (r.0.60 for all three plasma) was found for the
242315 and 314994 plasma between the 24/1/14 PBMC assay and
the TZMbl_PV assay. The correlation was statistically significant
(p,0.04). The strongest correlation (r.0.69) was observed between
the two PV assays (TZMbl-PV and GHOST_PV). Correlations for
all three plasma were significant (p,0.01).
Evaluation of plasma vs. antibodies in the 24/1/14
extended incubation PBMC assay. The neutralization
Table 3. Clinical information ITM patients.
Patient code Donor subtype Patient origin Age
Years after 1
st
diagnosis
Viremia
RNA copies/ml
CD4 count
cells/ul HAART
242315-HJ C Democratic Republic of the Congo 45 12 62 277 2003–2005, 2007-onwards
314994-HGN CRF02_AG Republic of Guinea 41 10 125 765 no treatment
529552-HK CRF02_AG Republic of Ghana 31 1 150 623 no treatment
doi:10.1371/journal.pone.0025488.t003
Table 4. Neutralization profile of HJ, HGN and HK patient
plasma against a panel of 26 primary viruses belonging to 6
subtypes in the 24/1/14 extended incubation PBMC assay.
24/1/14 PBMC (24 strains)
Subtype Strain 242315-HJ 314994-HGN 529552-HK
A VI 191 96,0 80,5 97,7
92UG37 98,2 96,1 62,0
VI 820 60,2 87,4 65,3
VI 1031 97,2 55,3 99,8
B8 9 , 6 91,5 91,9 96,0
93US076 99,0 84,9 E
92US077 91,1 80,0 70,5
93US143 66,1 80,0 0,0
C VI 829 85,9 91,1 99,0
VI 882 99,4 63,7 32,4
VI 1144 99,0 74,3 95,4
VI 1358 94,8 93,7 96,0
D VI 656 84,9 E 73,7
VI 693 84,9 25,9 E
VI 824 78,1 66,1 69,1
VI 865 89,8 48,7 87,1
CRF01 VI 1249 88,3 30,8 38,3
CA 10 96,4 E 80,0
VI 1888 89,5 24,1 66,1
THA92_022 80,0 E 32,4
CRF02 VI 1090 94,8 91,1 99,8
VI 2680 0,0 73,7 88,3
CI 20 93,1 88,3 97,7
CA 18 97,0 97,2 59,3
VI 1380 0,0 96,1 96,4
VI 2727 84,5 E 69,8
% Neutralization obtained with 1:20 plasma dilution, $80% reduction in virus
titer is highlighted, E: enhancement of infection.
doi:10.1371/journal.pone.0025488.t004
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mAbs for the 24/1/14 extended incubation PBMC assay in
Table 6.
The mAbs clearly neutralized a much more restricted range of
isolates than the plasma. 242315-HJ plasma and HJ16 mAb both
neutralized the subtype C isolate VI829, the subtype D CI 13 and
two of the three CRF02_AG isolates, VI 1090 and CA18. 314994-
HGN plasma and HGN194 mAb as well as 529552-HK plasma
and HK20 mAb neutralized SF162 (B) and 92Br025 (C) while
HGN194 mAb also neutralized VI 191 (A) and 89.6 (B). In
Table 5. Neutralization profile of patient plasma in different HIV-1 neutralization assays.
Infectious virus Pseudo virus
242315-HJ 24/1/14 1/2/7 1/24/14 TZMbl_IV TZMbl_PV GHOST_PV
A VI 191 96,0 E E 8,8 19,5 8,0
92RW009 E 80,0 32,4 16,2 33,8 16,7
B SF162 99,8 97,4 73,7 87,2 93,8 81,5
C VI 829 85,9 0,0 24,1 46,6 79,6 82,0
VI 882 99,4 EE 59,7 81,2 83,4
VI 1358 94,8 30,8 71,8 30,1 49,2 69,7
92Br025 97,7 80,0 94,2 43,9 75,4 59,9
D VI 824 78,1 E 0,0 17,1 18,4 46,5
CRF01 VI 1888 89,5 86,8 E 26,6 16,9 38,6
CRF02 VI 1090 94,8 88,5 0,0 41,7 48,1 43,0
CI 20 93,1 71,8 0,0 54,7 66,7 58,6
CA 18 97,0 96,0 66,1 77,6 91,2 82,4
Infectious virus Pseudo virus
314994-HGN 24/1/14 1/2/7 1/24/14 TZMbl_IV TZMbl_PV GHOST_PV
A VI 191 80,5 E E E 25,8 46,0
92RW009 E 66,1 32,4 16,5 28,6 63,9
B SF162 99,8 70,5 96,9 88,5 100,3 95,2
C VI 829 91,1 E E E 33,2 59,5
VI 882 63,7 E E E E 42,9
VI 1358 93,7 E 68,4 E E 18,6
92Br025 97,7 55,3 84,5 49,3 83,8 86,5
D VI 824 66,1 E 0,0 E E 36,5
CRF01 VI 1888 24,1 49,9 60,2 13,9 E 52,0
CRF02 VI 1090 91,1 0,0 84,9 46,7 94,7 92,4
CI 20 88,3 E 22,4 26,7 44,4 74,3
CA 18 97,2 47,5 62,8 60,4 82,3 83,3
Infectious virus Pseudo virus
529552-HK 24/1/14 1/2/7 1/24/14 TZMbl_IV TZMbl_PV GHOST_PV
A VI 191 97,7 0,0 E E 79,3 94,0
92RW009 41,1 E E 63,2 11,6 57,5
B SF162 99,9 91,5 90,9 93,6 100,0 97,5
C VI 829 99,0 55,3 41,1 E 98,0 97,1
VI 882 32,4 54,3 0,0 E 94,7 96,9
VI 1358 96,0 80,0 85,9 E 94,3 95,8
92Br025 99,5 55,3 93,2 93,3 98,2 86,9
D VI 824 69,1 45,0 E E 52,2 95,3
CRF01 VI 1888 66,1 70,5 30,8 E 67,0 90,4
CRF02 VI 1090 99,8 55,3 0,0 80,1 50,5 85,2
CI 20 97,7 55,3 22,4 E 97,2 96,8
CA 18 59,3 93,8 E 33,0 80,7 57,7
% Neutralization obtained with 1:20 plasma dilution, $80% reduction in virus titer is highlighted in bold for the PBMC assays, $50% reduction in virus titer is
highlighted in bold for the cell line based assays, E: enhancement of infection.
doi:10.1371/journal.pone.0025488.t005
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that growth of some viruses was strongly inhibited by the mAb, but
enhanced by the plasma (e.g. subtype A 92RW009 with 242315-
HJ plasma versus HJ16 mAb) or vice-versa (e.g. CRF02 strains
with 314994-HGN plasma versus HGN194 mAb). This type of
inconsistency was also observed by the group of Nussenzweig
when they compared their new mAbs with results from the original
plasma [16]. Some neutralization-sensitive isolates, CA1 (A), MN
(B), BaL (B) and CI 13 (D), were added to the panel in table 6.
However, there was only a limited increase in range with HJ16
mAb reaching 80% neutralization against CI 13 (D) and HGN194
mAb almost neutralizing BaL (B) to 80%. HK20 mAb had no
activity against any of the extra isolates.
Influence of assays on neutralization profile of the three
new antibodies
While the plasma demonstrated their broadest range of
neutralization in the 24/1/14 assays they also showed activity in
the other PBMC and cell-line assays. Since it is possible that the
mAbs could share these activities we extended their evaluation to
assays with the different formats (Table 7).
The range of HIV-1 isolates neutralized by both the plasma and
mAbs is greatest in the extended incubation 24/1/14 PBMC assay
while only three of the 36 mAb/isolate combinations show significant
neutralizing activity in the extended absorption 1/24/14 PBMC assay.
The HJ16 mAb neutralizes three (SF162, VI 1888 and VI 1090) of the
six isolates (92RW009, 93Br025 and CA18) neutralized by the plasma
in 1/2/7 PBMC assays (table 5). The HGN194 mAb neutralizes
SF162, VI 1888 and 92RW009 while the corresponding plasma do not
produce significant neutralization against any isolate in these assays.
The HK20 mAb only neutralizes VI 1888. When the absorption and
culture phases of the assay are extended to the 1/24/14 setup, HJ16
still neutralizes VI 1090, HGN194 neutralizes SF162 and VI 1888
while HK20 neutralizes VI 1090 for 80%.
With regard to cell line based assays, there is a good
concordance for HGN194 mAb and plasma in the GHOST-PV
assay. Four of these HGN194-PV combinations are also
neutralizing when the target cells are TZMbl. However, when
infectious virus is used 10/12 combinations are enhancing. HJ16
mAb neutralizes 92RW009 and VI 1090 in all three cell-line
assays while the corresponding plasma failed to do so in these
assays (see Table 5). Remarkably, however, 92RW009 was
neutralized by 242315-HJ plasma in the 1/2/7 PBMC assay
selectively and VI 1090 was neutralized by HJ plasma in both the
24/1/14 and the 1/2/7 PBMC assay. The HK20 mAb only
neutralizes VI 882 in the GHOST_PV assay, SF162 in the
TZMbl_PV assay and does not neutralize any infectious virus.
There was no consistent statistically significant correlation between
the levels of neutralization reached in the 24/1/14 PBMC assay
and the others except where only a few isolates were actually
neutralized or neutralization levels were low.
Independent evaluation of plasma and monoclonal
antibodies in TZMbl assay
In order to link the present and previous studies, plasma were
tested in TZMbl assays against a sub-panel of PV included in
supplementary table 2 of reference 7.
Comparisons are presented in Table 8.
Again, there were anomalies with mAbs neutralizing isolates
which were not neutralized by the corresponding plasma and vice
versa. Similarly, the mAbs showed a reduced range of neutrali-
zation relative to their corresponding plasma. Plasma from the
242315-HJ patient is very effective against the three tier 1 strains
and also against five out of 11 tier 2 strains. In contrast, the
corresponding HJ16 mAb is not able to neutralize the tier 1 strains
and although effective against six out of 11 tier 2 strains, these are
not always the same isolates as neutralized by the plasma. Plasma
from the 314994-HGN patient is able to neutralize all tier 1 strains
Table 6. Evaluation plasma vs. mAbs in the 24/1/14 extended incubation PBMC assay.
plasma vs mAbs 242315-HJ 314994-HGN 529552-HK
Subtype Strain plasma HJ16 mAb plasma HGN194 mAb plasma HK20 mAb
A VI 191 96,0 66,1 80,5 80,0 97,7 74,3
92RW009 E 96,0 E 71,8 41,1 88,3
CA 1 99,6 E 94,4 0,0 99,6 22,4
B SF162 99,8 0,0 99,8 84,5 99,9 88,3
MN E E 42,5 55,3 55,3 E
BaL 98,1 66,1 90,5 79,1 93,1 73,7
89.6 91,5 55,3 91,9 88,5 96,0 55,3
C VI 829 85,9 91,1 91,1 74,3 99,0 74,3
VI 882 99,4 E 63,7 22,4 32,4 0,0
VI 1358 94,8 41,1 93,7 E 96,0 0,0
92Br025 97,7 77,6 97,7 84,5 99,5 91,1
D VI 824 78,1 55,3 66,1 0,0 69,1 55,3
CI 13 99,8 80,0 49,9 55,3 96,9 42,5
CRF01 VI 1888 89,5 22,4 24,1 12,9 66,1 22,4
CRF02 VI 1090 94,8 99,4 91,1 E 99,8 0,0
CI 20 93,1 71,2 88,3 E 97,7 51,0
CA 18 97,0 80,0 97,2 0,0 59,3 E
Shown is % neutralization with $80% reduction in virus titer in bold. Plasma were tested at a 1 in 20 dilution, Abs were tested at a concentration of 50 mg/ml,
E: enhancement of infection.
doi:10.1371/journal.pone.0025488.t006
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neutralize the tier 1 strains and three out of 11 tier 2 strains.
However, again, these are not always the same strains that are
neutralized by the plasma. Plasma from the HK patient is able to
potently neutralize the three tier 1 strains but none of the tier 2
isolates while the HK20 mAb is effective against only one of the
three tier 1 strains and one of the 11 tier 2 isolates.
The proportion of isolates neutralized by an individual plasma
was also markedly dependent on the panel of HIV isolates used.
The patients’ plasma were initially selected in 24/1/14 PBMC
Table 7. Neutralization profile of mAbs in different HIV-1 neutralization assays.
Infectious virus Pseudo virus
HJ16 24/1/14 1/2/7 1/24/14 TZMbl_IV TZMbl_PV GHOST_PV
A VI 191 66,1 33,9 E 3,1 E E
92RW009 96,0 41,1 70,5 71,2 85,1 96,5
B SF162 0,0 80,0 E E 35,2 8,9
C VI 829 91,1 E E 13,3 61,3 66,1
VI 882 E 33,9 66,1 12,8 19,6 8,9
VI 1358 41,1 E E 9,1 11,4 E
92Br025 77,6 35,4 14,9 13,4 E E
D VI 824 55,3 41,1 18,7 3,4 29,4 12,1
CRF01 VI 1888 22,4 85,2 74,3 10,6 3,4 7,1
CRF02 VI 1090 99,4 99,4 98,5 97,2 100,0 100,0
CI 20 71,2 E E 11,5 22,0 E
CA 18 80,0 E 66,1 41,1 24,3 67,6
Infectious virus Pseudo virus
HGN194 24/1/14 1/2/7 1/24/14 TZMbl_IV TZMbl_PV GHOST_PV
A VI 191 80,0 70,5 E E 6,3 35,0
92RW009 71,8 84,5 E E E 42,9
B SF162 84,5 98,6 99,5 33,0 99,9 98,5
C VI 829 74,3 E E E 66,1 74,6
VI 882 22,4 E 42,5 E E 22,2
VI 1358 E 4,5 12,9 E E 24,6
92Br025 84,5 24,1 41,1 5,1 56,7 64,7
D VI 824 0,0 49,9 55,3 E E 26,6
CRF01 VI 1888 12,9 85,2 84,9 E E 25,1
CRF02 VI 1090 E 0,0 71,2 E E 64,2
CI 20 E 24,1 E E 61,6 52,1
CA 18 0,0 E 24,1 E E 50,9
Infectious virus Pseudo virus
HK20 24/1/14 1/2/7 1/24/14 TZMbl_IV TZMbl_PV GHOST_PV
A VI 191 74,3 36,9 E 7,5 12,2 26,0
92RW009 88,3 E 32,4 E E 21,9
B SF162 88,3 E 75,5 16,7 82,0 29,4
C VI 829 74,3 E E 17,9 20,7 22,5
VI 882 0,0 E 66,1 16,2 4,5 50,6
VI 1358 0,0 73,1 E E 18,1 13,8
92Br025 91,1 35,4 E 22,5 15,9 37,9
D VI 824 55,3 E 41,1 4,6 31,8 29,5
CRF01 VI 1888 22,4 91,3 69,8 23,6 9,4 44,9
CRF02 VI 1090 0,0 41,1 80,0 11,8 E 20,3
CI 20 51,0 E E 31,0 16,5 17,3
CA 18 E E 55,3 21,8 E 31,4
% Neutralization obtained with 1:20 plasma dilution, $80% reduction in virus titer is highlighted in bold for the PBMC assays, $50% reduction in virus titer is
highlighted in bold for the cell line based assays, E: enhancement of infection.
doi:10.1371/journal.pone.0025488.t007
Neutralization of Plasma vs. Antibodies
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25488assays and the ITM panel of 14 primary infectious HIV-1 isolates
(Table 4). In the smaller, modified panel of PV used in Antwerp
(Table 5), the 242315-HJ plasma neutralized six isolates (50%), the
314994-HGN plasma neutralized four (33.3%) while the 529552-
HK plasma neutralized all but one (92%) of the PV in the TZMbl
assay. The same plasma neutralized eight (57.1%; HJ16), seven
(50%; HGN 194) and only three (21.4%; HK 20) of the 14 isolates
tested at the Beth Israel Deaconess Medical Center (BIDMC).
Discussion
The present study is based on an extensive program to employ
naturally occurring broadly neutralizing Abs from HIV-infected
patients as templates for immunogen design against A, C and
CRF02 primary viruses. From the memory B cell interrogation of
such patients many mAbs were generated, but only three of these
(HJ16, HGN194 and HK20) showed interesting novel broad
neutralizing capacity. Since the plasma and ensuing mAb were
selected in different neutralization assays, we wanted to explore
and understand the behaviour of these exceptional plasma and
mAbs in various neutralization assays, based on PBMC or cell
lines, using primary infectious viruses or non-replicating PV.
A first observation was that the three patients, from whom the
neutralizing mAbs were generated, showed an intermediate
breadth of neutralization, preferentially neutralizing subtype A
(HGN patient) or C (HJ patient) or A and C (HK patient), which
did not correspond with the subtypes of their infection. Another
remarkable observation is that they all showed a low viral load
without treatment at the time of sampling. Only patient HGN had
the profile of a viraemic controller, whereas HJ was a chronic
progressor and patient HK was probably still in an early phase.
In the last two years several groups have reported the discovery
of new and promising Abs [17,18,19]. The HJ16, HGN194 and
HK20 Abs obtained by our consortium were amongst those
obtained by means of the interrogation of rather chronically HIV-
1 infected patients. In the present study, the HGN194 patient was
infected for at least 10 years and seemed to naturally control her
HIV-1 infection, the HK20 patient may not have been infected for
longer than a year and the HJ16 patient regularly required
antiretroviral therapy to control her viral load. These data confirm
that neutralizing Ab development does not protect against disease
progression. Similarly, some of the broadest neutralizing plasma
were obtained from patients who urgently required HAART (e.g.
HY-plasma table 2, clinical history not shown).
A side-by-side comparison of the different neutralization assays
used for characterization of these patients’ plasma and the newly
isolated Abs showed that the broadest spectrum of strains and
subtypes was neutralized in the PV assays as well as in the 24/1/
14 extended incubation PBMC assay with primary virus. In
contrast, the classical short incubation phase assays as well as the
extended absorption phase PBMC assays showed a reduction in
the number of neutralized strains. The TZMbl assay using
primary virus also showed this restricted profile despite the fact
that it has an extended absorption phase in common with the cell
line PV assays. Results for the three patient plasma that were
selected for their cross-neutralizing capacity in the 24/1/14
PBMC assay correlated with those obtained in the TZMbl_PV
assay for only two patients. It is unusual that these two
substantially different techniques result in comparable neutraliza-
tion profiles (own results and [20]). Both PV based assays
correlated strongly with each other.
Another observation was that all three isolated Abs have a
narrower and partially different neutralization spectrum relative to
the corresponding plasma in the extended incubation PBMC and
TZMbl PV assays. Results with the HJ16 mAb from the PBMC,
TZMbl and GHOST assays show good correspondence while for
the HGN194 mAb the GHOST neutralization responses are
broader. The HK20 mAb shows little to no neutralization in either
the TZMbl or GHOST assays. Neutralization breadth across
subtypes is unlikely to be due to endotoxin since plasma are
negative in conventional assays where absorption phases (and
therefore contact between plasma and cells) are longer [21].
Several factors may be responsible for the reduction in the range
of isolates neutralized by the mAbs. One reason could be the
polyclonal character of the Abs in the plasma. Cross-neutralization
may require interaction between Abs acting at several epitopes. In
Table 8. Evaluation plasma vs. Ab in the TZMbl pseudovirus assay.
242315-plasma HJ16 314994-plasma HGN194 529552-plasma HK20
Tier 1 MW965.26 C 8552 .50 20050 ,0.02 22466 17.3
SF162.LS B 2116 .50 1210 ,0.02 3529 .150
BaL.26 B 112 .50 109 0.10 180 .150
Tier 2 Q168.a2 AD 71 0,04 347 .50 27 .150
Q769.d22 A ,20 .50 721 .50 ,20 31.5
Q461.e2 A 194 0,2 58 .50 ,20 .150
RHPA4259.7 B 831 ,0.02 ,20 35.4 ,20 .150
AC10.0.29 B 57 .50 535 .50 26 .150
Du151.2 C 173 .50 61 .50 31 .150
ZM109F.PB4 C 24 2.9 43 2.2 ,20 .150
96ZM651.2 C 132 0.20 88 .50 42 .50
T257-31 CRF02_AG ,20 17 64 .50 ,20 .150
CH110.2 CRF07_BC 204 .50 ,20 .50 ,20 .150
CH181.12 CRF07_BC 69 43.9 107 49.6 40 .150
Plasma were tested at the Beth Israel Deaconess Medical Center with different dilutions starting from 1 in 20, results are shown in ID50 values. Abs were tested at
different concentrations starting from 150 mg for their capacity to neutralize HIV-1 PV, results are shown in IC50 values (mg/ml). In bold: plasma ID50 $1 in 100, Ab IC50
#50 mg (see Mat & Meth).
doi:10.1371/journal.pone.0025488.t008
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plasma would not be possible when an average of only one to two
neutralizing mAb were isolated. This would be buttressed by
methods to directly determine the number of individual neutral-
izing antibody clones in the patient’s repertoire. We will also
address this issue in new studies but this has also been examined by
the group of Guan and Lewis [22]. Obviously, combining more
isolated mAb might correspond better to the plasma results when
additive and synergistic effects between Abs could be unveiled.
Unfortunately, we did not obtain more mAbs for the 242315-HJ
and 529552-HK patients. Although we did obtain more mAbs
from the 314994-HGN patient, none of these, except for
HGN194, were neutralizing in either the HOS or TZMbl assays.
Nevertheless, there may be ‘missing Abs’ as has been previously
suggested by the groups of Guan and Nussenzweig [16,22].
However, the ‘non-neutralizing’ mAbs may still be relevant in the
wider context since they could have other effector mechanisms
such as Ab-dependent cell-mediated virus inhibition (ADCVI) or
Ab-dependent cellular cytotoxicity (ADCC) through their FccRs
[23,24,25].
An alternative explanation for why relatively few neutralizing
mAb were obtained is that the primary screen was binding to
monomeric or trimeric envelope protein in ELISA and this
procedure might not be optimal. In the Walker study [17], it was
shown that the most potent Abs did not bind in an ELISA and even
Abs that did bind had a low neutralizing profile. The inference was
that specific quaternary protein structures should be used in a
primary screening. This issue is being addressed with the most
recent samples under interrogationat IRBwithinourconsortium. It
should also be noted that the Abs in the plasma probably originate
in the plasma cells of the bone marrow while the mAbs are isolated
from memory B cells in the circulation. These two cell populations
may not produce the same range of Abs. It should be possible to
culture individual plasma cells, clone their heavy and light chain
variable regions and identify the IgG or IgA repertoires produced.
Selection of the patients from whom the mAbs were isolated was
extremely assay dependent. The patients who gave the three
interesting mAbs would not have been selected if any of the
alternative assays had been used. The influence of target cells on
neutralization has already been observed both by us and others
[10,20,26,27]. In particular, there is a three way interaction effect
between the virus, antibody and target cells. Especially MPER
specific Abs are more potent in PBMC based assays [4,26,27].
Since our data show that the HJ, HK and HGN patients are more
potent in PBMC neutralization assays with an extended
incubation phase it could be envisioned that these special patients
could have a high proportion of gp41 specific Abs in their plasma.
In the past, naturally occurring crosssubtype neutralizing Abs have
already been used as templates for immunogen design but in most of
these cases patients were selected using either the classical short
PBMCassay(1/2/7format)orPVassaysandourresultsclearlyshow
that a different group of patients is selected by the extended
incubation PBMC assay (24/1/14 format). Testing the patient
plasma against primary strains is also more stringent since the
molecularlyclonedPVseemtobemoreeasilyneutralized.Hence,we
believe that our selection proced u r ea g a i n s tt h ep r i m a r yI T Mp a n e l
provided us with patients that had more potent responses.
A possible reason for any increased sensitivity of primary vs.
pseudo viruses for identifying patients with potent neutralizing Abs
could be the higher number of envelope glycoprotein spikes on the
primary viruses relative to the PV [20,28]. An alternative factor
might be the density of (co)receptors on target cells, which has
been implied by Corti et al who reported potent neutralization by
HK20 in the HOS assays but almost no potency in TZMbl assays
[2,3]. Since HK20 recognizes an epitope in the gp41 region this
could partially be explained by the high level of CCR5 expression
on the TZMbl cells making it more difficult for anti-gp41 Abs to
be effective [2,29]. Also, the pathway employed by PV to enter
TZMbl cells may be relevant so that HK20 could have been
hindered by events following uptake into an endosome [30].
Since the non-replicating PV constructs could not be assessed in
the primary target cells the recent development of molecularly
cloned constructs in a Renilla replication competent backbone is
certainlya step forwardinthe development ofa standardizedPBMC
based neutralization assay to assess neutralization in primary cells
[31,32]. It remains elusive whether the HJ16, HGN194 and HK20
mAbswould have beenobtained fromotherpatients.HK20 like Abs
have been detected through ELISA and although the neutralizing
capacity of this fraction was not shown it still provides proof that a
significant number of HIV-1 infected patients have responded to the
gp41-HR1 region which is only briefly exposed [2,3].
Evenafteralmost30yearsofHIVresearchandtheongoingsearch
for correlates of protection, there is still a critical need to determine
how effective different types of antibody effector mechanisms can be
in prevention of HIV-1 infection. Although many groups have tried
to identify which neutralization assay can predict in vivo protection,
this issue is still open to debate [33]. In several SIV and SHIV
macaque studies neutralizing mAbs have correlated with protection
[34,35,36,37,38,39,40,41,42,43], but there are also multiple counter
examples [44,45]. In this context, the most compelling demonstration
that pre-existing Abs can be protective comes from passive
immunization studies with either IgG or mAbs [28,34,38,39,40,
41,42,43,46,47,48,49]. The most recent study uses the HGN194
mAb against a SHIV strain containing an ‘early’ envelope and
emphasizes the importance of potent neutralizing Abs that confer
protection against a heterologous mucosal challenge [4]. The latter is
highlysignificant since future vaccines will need to be effective against
these relatively resistant early founder strains before infection is
established in vivo [50].
Taken together our observations show that a single neutralizing
mAb from each of the three patients does not reflect the major
neutralizing spectrum of the patients’ plasma and there is no
apparent correlation of the mAbs targeting HIV strains belonging
to the subtype of virus infecting the patient. It is quite evident that
different neutralization assays yield different results and it is still
unclear which one is most predictive or suited to obtain
neutralizing mAbs. Nevertheless, the strategy used for selection
of plasma (in an extended incubation PBMC assay) and selection
of mAb (based on ELISA binding and neutralizing capacity in a
HOS_PV assay) yielded interesting new mAbs. A better
understanding of in vitro neutralization characterizations of
patient plasma and Abs and will hopefully lead to more effective
ways of discovering new Abs that ultimately can be used for HIV-1
immunogen design and subsequent vaccine development.
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